产品
编 号：F745149
分子式：C19H21F3N2OS
分子量：382.44
分子式：C19H21F3N2OS
分子量：382.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1432445-15-2
产品详情
生物活性：
NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes.
体内研究：
NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel.NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability.Animal Model:Male C57BL/6 mice
Dosage:10 mg/kg
Administration:IV or PO; single dosage (Pharmacokinetics Analysis)
Result:Produced no observable toxic effects at 10 mg/kg by IV or PO; exhibited a short half-life of 0.45 h and high plasma clearance; exhibited high mouse and human serum protein binding, as well as moderate bioavailability (21.4%).
NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes.
体内研究：
NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel.NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability.Animal Model:Male C57BL/6 mice
Dosage:10 mg/kg
Administration:IV or PO; single dosage (Pharmacokinetics Analysis)
Result:Produced no observable toxic effects at 10 mg/kg by IV or PO; exhibited a short half-life of 0.45 h and high plasma clearance; exhibited high mouse and human serum protein binding, as well as moderate bioavailability (21.4%).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备